{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:23:05Z","timestamp":1787671385928,"version":"build-2736575974"},"reference-count":41,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Health Commission Capacity Building and Continuing Education Centre Cancer Pain Management","award":["PMT1001-1"],"award-info":[{"award-number":["PMT1001-1"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-1-4061"],"award-info":[{"award-number":["2022-1-4061"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602200"],"award-info":[{"award-number":["2022YFC3602200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602201"],"award-info":[{"award-number":["2022YFC3602201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602202"],"award-info":[{"award-number":["2022YFC3602202"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602203"],"award-info":[{"award-number":["2022YFC3602203"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602205"],"award-info":[{"award-number":["2022YFC3602205"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Fibromyalgia (FM) is a prevalent chronic pain condition that significantly impairs quality of life. The current treatments for FM still have some disadvantages and limitations. Pregabalin, a standard pharmacological treatment, provides relief for some patients but is associated with dose-dependent adverse events (AEs) and incomplete efficacy, highlighting a significant unmet clinical need. Mirogabalin, as a novel \u03b12\u03b4 ligand similar to pregabalin but with distinct binding properties, has shown a favourable safety profile and potential analgesic effects in preclinical studies and trials for other neuropathic pain conditions. However, data on its efficacy in FM are limited and no studies have directly compared mirogabalin with pregabalin in an Asian FM population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a prospective, multicentre, randomised, open-label, blinded endpoint trial to compare the efficacy and safety of mirogabalin versus pregabalin for the management of pain and other core symptoms in adult patients with FM. This study will be conducted at the Department of Pain Management, Beijing Tiantan Hospital, the First Affiliated Hospital of Nanchang University, Chongqing University Three Gorges Hospital, the First Affiliated Hospital of Army Medical University and the Affiliated Hospital of Yanbian University. Patients aged over 18 years, diagnosed with FM according to the 2016 Revisions to the 2010\/2011 FM diagnostic criteria, will be enrolled. 674 qualified patients experiencing moderate-to-severe FM will be randomly assigned to either the pregabalin group or the mirogabalin group in a 1:1 ratio. Treatment will involve individualised dose titration based on treatment response and tolerability. All participants will be followed for a duration of 12 weeks. The primary outcome will be the proportion of patients achieving a pain reduction of at least 50% at 12 weeks. Secondary endpoints will include the average pain intensity, the worst pain intensity, the Revised FM Impact Questionnaire, the Brief Pain Inventory severity and interference subscales, the Short-Form 36 Health Survey, the Medical Outcomes Study Sleep Scale, the Beck Depression Inventory-II, AEs throughout the study. An open-label administration is selected to reflect real-world clinical practice and to allow individualised dose titration according to tolerability and response, while blinded endpoint assessment is implemented to minimise evaluation bias and preserve methodological rigour.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University (KY2025-217-03), the First Affiliated Hospital of Nanchang University (IIT (2026) Clinical Ethics Review no. 676), Chongqing University Three Gorges Hospital (2026 Scientific Ethics Review no. 41), the Affiliated Hospital of Yanbian University (Yan Medical Ethics no. 20260275) and the First Affiliated Hospital of Army Medical University (AIIT2026081KX). All participants will provide written informed consent prior to enrolment. This study will be conducted in accordance with the Declaration of Helsinki. Findings from this study will be disseminated through peer-reviewed journals and at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07157852\">NCT07157852<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-110911","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:41:40Z","timestamp":1787668900000},"page":"e110911","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of mirogabalin in patients with fibromyalgia: protocol for a multicentre, Prospective, Randomised, Open-label, Blinded Endpoint (PROBE) study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07157852","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07157852","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Minying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pain Management, The First People\u2019s Hospital of Yunnan Province, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiugao","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pain Management, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pain Management, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pain Management, China-Japan Friendship Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pain Management, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pain Management, The First People\u2019s Hospital of Yunnan Province, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pain Management, China-Japan Friendship Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pain Management, China-Japan Friendship Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pain Management, China-Japan Friendship Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pain Management, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pain Management, The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-0355","authenticated-orcid":false,"given":"Fang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bifa","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pain Management, China-Japan Friendship Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026082507350762000_16.8.e110911.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2026082507350762000_16.8.e110911.2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/art.38905","article-title":"The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria","volume":"67","author":"Jones","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026082507350762000_16.8.e110911.3","doi-asserted-by":"publisher","DOI":"10.1186\/ar2715"},{"key":"2026082507350762000_16.8.e110911.4","doi-asserted-by":"crossref","unstructured":"Lacasse A , Bourgault P , Choini\u00e8re M . Fibromyalgia-related costs and loss of productivity: a substantial societal burden. BMC Musculoskelet Disord 2016;17. doi:10.1186\/s12891-016-1027-6","DOI":"10.1186\/s12891-016-1027-6"},{"key":"2026082507350762000_16.8.e110911.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"2026082507350762000_16.8.e110911.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00506-w"},{"key":"2026082507350762000_16.8.e110911.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.98"},{"key":"2026082507350762000_16.8.e110911.8","doi-asserted-by":"crossref","unstructured":"Wiffen PJ , Derry S , Moore RA , et al . Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev 2013;2019. doi:10.1002\/14651858.CD010567.pub2","DOI":"10.1002\/14651858.CD010567.pub2"},{"key":"2026082507350762000_16.8.e110911.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.944"},{"key":"2026082507350762000_16.8.e110911.10","doi-asserted-by":"crossref","unstructured":"Welsch P , \u00dc\u00e7eyler N , Klose P , et al . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev 2018;2. doi:10.1002\/14651858.CD010292.pub2","DOI":"10.1002\/14651858.CD010292.pub2"},{"key":"2026082507350762000_16.8.e110911.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.20076"},{"key":"2026082507350762000_16.8.e110911.12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000011424","article-title":"What is the mechanism of therapeutic and adverse effects of gabapentinoids?","volume":"96","author":"Benarroch","year":"2021","journal-title":"Neurology"},{"key":"2026082507350762000_16.8.e110911.13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026082507350762000_16.8.e110911.14","doi-asserted-by":"crossref","unstructured":"Derry S , Cording M , Wiffen PJ , et al . Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016;2019. doi:10.1002\/14651858.CD011790.pub2","DOI":"10.1002\/14651858.CD011790.pub2"},{"key":"2026082507350762000_16.8.e110911.15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14737175.2018.1508344","article-title":"Controlled-release pregabalin in the treatment of fibromyalgia","volume":"18","author":"Alciati","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"2026082507350762000_16.8.e110911.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep432"},{"key":"2026082507350762000_16.8.e110911.17","doi-asserted-by":"crossref","unstructured":"Mathieson S , Lin C-W , Underwood M , et al . Pregabalin and gabapentin for pain. BMJ 2020;369. doi:10.1136\/bmj.m1315","DOI":"10.1136\/bmj.m1315"},{"key":"2026082507350762000_16.8.e110911.18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01070-8"},{"key":"2026082507350762000_16.8.e110911.19","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.247551"},{"key":"2026082507350762000_16.8.e110911.20","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001501"},{"key":"2026082507350762000_16.8.e110911.21","doi-asserted-by":"crossref","first-page":"1491570","DOI":"10.3389\/fphar.2024.1491570","article-title":"Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026082507350762000_16.8.e110911.22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40122-024-00617-2","article-title":"A phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in chinese patients with diabetic peripheral neuropathic pain","volume":"13","author":"Guo","year":"2024","journal-title":"Pain Ther"},{"key":"2026082507350762000_16.8.e110911.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1044"},{"key":"2026082507350762000_16.8.e110911.24","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1093\/pm\/pnw342","article-title":"Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study","volume":"18","author":"Merante","year":"2017","journal-title":"Pain Med"},{"key":"2026082507350762000_16.8.e110911.25","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13013"},{"key":"2026082507350762000_16.8.e110911.26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00210-019-01628-z","article-title":"Analgesic effects of mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia","volume":"392","author":"Saeki","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026082507350762000_16.8.e110911.27","doi-asserted-by":"crossref","first-page":"111647","DOI":"10.1016\/j.biopha.2021.111647","article-title":"Mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, improves cognitive impairments in repeated intramuscular acidic saline injection model rats, an experimental model of fibromyalgia","volume":"139","author":"Murasawa","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026082507350762000_16.8.e110911.28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s43440-020-00103-4","article-title":"Anxiolytic-like effects of mirogabalin, a novel ligand for \u03b12\u03b4 ligand of voltage-gated calcium channels, in rats repeatedly injected with acidic saline intramuscularly, as an experimental model of fibromyalgia","volume":"72","author":"Murasawa","year":"2020","journal-title":"Pharmacol Rep"},{"key":"2026082507350762000_16.8.e110911.29","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1080\/03007995.2019.1629757","article-title":"Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study","volume":"35","author":"Arnold","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026082507350762000_16.8.e110911.30","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s12325-022-02424-7","article-title":"Safety, tolerability and pharmacokinetics of single and multiple doses of mirogabalin in healthy chinese participants: a randomized, double-blind, placebo-controlled study","volume":"40","author":"Li","year":"2023","journal-title":"Adv Ther"},{"key":"2026082507350762000_16.8.e110911.31","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.2147\/JPR.S274562","article-title":"Efficacy and safety of ASP0819 in patients with fibromyalgia: results of a proof-of-concept, randomized, double-blind, placebo-controlled trial","volume":"13","author":"Arnold","year":"2020","journal-title":"J Pain Res"},{"key":"2026082507350762000_16.8.e110911.32","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13483894"},{"key":"2026082507350762000_16.8.e110911.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"2026082507350762000_16.8.e110911.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00101-3"},{"key":"2026082507350762000_16.8.e110911.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141196"},{"key":"2026082507350762000_16.8.e110911.36","doi-asserted-by":"crossref","unstructured":"Bennett RM , Friend R , Jones KD , et al . The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009;11. doi:10.1186\/ar2783","DOI":"10.1186\/ar2783"},{"key":"2026082507350762000_16.8.e110911.37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jphys.2015.07.001","article-title":"The Brief Pain Inventory (BPI)","volume":"62","author":"Poquet","year":"2016","journal-title":"J Physiother"},{"key":"2026082507350762000_16.8.e110911.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6890.1437"},{"key":"2026082507350762000_16.8.e110911.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2004.07.006"},{"key":"2026082507350762000_16.8.e110911.40","doi-asserted-by":"publisher","DOI":"10.1159\/000066239"},{"key":"2026082507350762000_16.8.e110911.41","doi-asserted-by":"crossref","unstructured":"Rampakakis E , Ste-Marie PA , Sampalis JS , et al . Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open 2015;1. doi:10.1136\/rmdopen-2015-000146","DOI":"10.1136\/rmdopen-2015-000146"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-110911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:41:44Z","timestamp":1787668904000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-110911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,25]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2025-110911"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-110911","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}